心力衰竭患者的伊瓦布拉丁:一个系统的文献审查
Zeba M Khan1, Jean Baptiste Briere2, Elzbieta Olewinska3
1Zebgene LLC, Malvern, PA, USA.
Journal of market access & health policy
|October 9, 2023
概括
伊瓦布拉丁有效地降低了心力衰竭患者的住院和死亡率,心力衰竭患者的心力衰竭减少喷射率 (HFrEF). 这种心率降低药物可以改善生活质量,而不会增加不良事件.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 减少喷射分数 (HFrEF) 的心力衰竭具有显著的发病率和死亡率风险.
- 无法控制的静止心率是HFrEF患者不良结果的关键风险因素.
- 目前的疗法旨在控制症状并改善HFrEF的预后.
研究的目的:
- 在HFrEF中系统地审查伊瓦布拉丁的疗效,安全性和患者报告的结果 (PRO).
- 综合来自随机对照试验 (RCT) 和观察性研究的证据.
- 评估伊瓦布拉丁对临床终点和生活质量的影响.
主要方法:
- 电子数据库的系统文献搜索截至2021年7月.
- 在HFrEF中包括报告伊瓦布拉丁的RCT和观察性研究.
- 对疗效,安全性和PROs数据的分析.
主要成果:
- 伊瓦布拉丁显著降低了复合结果 (高频率住院或心血管死亡).
- 观察性研究表明,使用伊瓦布拉丁可显著降低死亡率.
- 伊瓦布拉丁改善了心率,喷射率 (EF) 和与健康有关的生活质量 (QoL),并具有可比的不良事件风险.
结论:
- 伊瓦布拉丁在心率控制,降低HF住院和改善HFrEF死亡率方面提供了好处.
- 药物增强了射出分数,改善了患者的生活质量.
- 这些好处在没有显著增加不良事件的总体风险的情况下实现.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
445
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
445
Heart Failure IV: Classification and Diagnostic Evaluation
19
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
19
Heart Failure Drugs: Inotropic Agents
601
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
601
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure V: Medical Management
10
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
10
Heart Failure II: Pathophysiology
14
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14


